Prab at 01:31, 19 March 2025

2025-03-19T01:31:13Z

← Older revision		Revision as of 01:31, 19 March 2025
Line 45:		Line 45:
	{{Pharma-stub}}		{{Pharma-stub}}
	{{No image}}		{{No image}}
	~~__NOINDEX__~~

Prab: CSV import

2025-03-17T04:06:04Z

CSV import

← Older revision		Revision as of 04:06, 17 March 2025
Line 45:		Line 45:
	{{Pharma-stub}}		{{Pharma-stub}}
	{{No image}}		{{No image}}
			__NOINDEX__

Prab: CSV import

2025-02-10T05:03:41Z

CSV import

← Older revision		Revision as of 05:03, 10 February 2025
Line 44:		Line 44:
	[[Category:Cancer research]]		[[Category:Cancer research]]
	{{Pharma-stub}}		{{Pharma-stub}}
			{{No image}}

Prab at 14:26, 17 September 2023

2023-09-17T14:26:52Z

New page

'''Agent studies''' play a pivotal role in the realm of clinical trials, specifically in the context of assessing the [[chemotherapy|chemotherapeutic]] potential of substances. The overarching goal of these studies is to evaluate if a substance can inhibit or prevent cancer. They form a foundational step in the comprehensive process of developing new cancer drugs, paving the way for more advanced studies.

=== Purpose of an Agent Study ===

The core purpose of an agent study is to:
* Understand the chemotherapeutic properties of a substance.
* Evaluate the substance's efficacy in preventing or inhibiting [[cancer]].
* Form a basis for further research and validation in a clinical setting.

=== Cytotoxic vs. Cytostatic Agents ===

One of the primary outcomes of agent studies is to categorize the substance under investigation as either '''cytotoxic''' or '''cytostatic'''.

* '''[[Cytotoxic agents]]''': These are chemicals that induce tumor shrinkage. They operate by killing or severely damaging the tumor cells.
* '''[[Cytostatic agents]]''': These substances act by slowing down or halting tumor growth and metastasis. They do not necessarily kill the tumor cells but prevent them from proliferating.

It's vital to discern which effect an agent exhibits to devise an appropriate clinical trial. Trials focusing on cytotoxic agents typically examine tumor shrinkage in correlation to dose. Trials for cytostatic agents can be more challenging to design due to their inhibitory action on tumor growth.

=== Phase I Clinical Trials ===

'''Phase I trials''' serve as the initial phase in clinical trials and have specific objectives:

* Determine the '''maximum tolerated dose (MTD)''' of an agent.
* Establish a baseline for dosages to be used in subsequent Phase II trials.
* Evaluate toxicity levels, especially for cytotoxic agents.
It's noteworthy that cytostatic agents often manifest biological effects without being toxic. Hence, when designing trials for cytostatic agents, both toxicity and a biologic end point response to varying doses should be evaluated.

=== Synonyms ===
* [[Chemoprevention]] study

=== Importance in Cancer Research ===

Agent studies stand as a cornerstone in cancer research, enabling researchers to:
* Weed out ineffective or overly toxic substances early in the research process.
* Focus resources on potential drugs with promising results.
* Customize trial designs based on the properties of the agent, ensuring the highest likelihood of capturing meaningful results.

=== See Also ===
* [[Clinical trial phases]]
* [[Chemotherapy]]
* [[Oncology]]
* [[Tumor growth inhibition]]
* [[Cancer]]
[[Category:Cancer research]]
{{Pharma-stub}}

Agent study - Revision history

Prab at 01:31, 19 March 2025

Prab: CSV import

Prab: CSV import

Prab at 14:26, 17 September 2023